Drug Search Results
More Filters [+]

Midazolam

Alternative Names: midazolam, dormicum, versed, epistatus, MELT-210, MELT210, MELT 210, midazolam in 0.9% sodium chloride, nayzilam, seizalam, midozalam hydrochloride
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Midazolam injection is used before medical procedures and surgery to cause drowsiness, relieve anxiety, and prevent any memory of the event. It is also sometimes given as part of the anesthesia during surgery to produce a loss of consciousness. Midazolam injection is also used to cause a state of decreased consciousness in seriously ill people in intensive care units (ICU) who are breathing with the help of a machine. Midazolam injection is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow relaxation and decreased consciousness. (Sourced from: https://medlineplus.gov/druginfo/meds/a609014.html)

Mechanisms of Action: GABA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Epilepsy | Seizures | Anastesia Related | Status Epilepticus

Known Adverse Events: Headache | Apnea | Status Epilepticus | Airway Obstruction

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Midazolam

Countries in Clinic: Belgium, China, Germany, Hungary, South Africa, Sweden, United Kingdom, United States

Active Clinical Trial Count: 49

Highest Development Phases

Phase 3: Other|Seizures

Phase 2: Cataract

Phase 1: Body Weight Changes|Breast Cancer|COVID-19|Chronic Obstructive Pulmonary Disease|Drug Hypersensitivity|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Gout|Healthy Volunteers|Heart Failure, Chronic|Heart Failure, Systolic|Helicobacter Infections|Hepatitis B, Chronic|Influenza, Human|Malaria|Male Breast Cancer|Non-Small-Cell Lung Cancer|Obesity|Overweight|Pain Unspecified|Prostate Cancer|Psoriasis|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

U1111-1307-0132

P1

Active, not recruiting

Overweight|Obesity

2025-11-12

D8532C00006

P1

Recruiting

Male Breast Cancer

2025-02-23

HM005PS1S08

P1

Not yet recruiting

Psoriasis

2025-02-12

J5C-MC-FOAF, DC-853104

P1

Recruiting

Healthy Volunteers

2024-12-31

Recent News Events